Shopping carts.

Could COVID-19 Affect Production of Erectile Dysfunction Drugs?

The worldwide spread of COVID-19 threatens to disrupt the pharmaceutical supply chain, prompting an increase in the prices of the drugs most affected. Now might be a good time to stock up on your ED drugs.

The novel coronavirus known as COVID-19 struck first in China, putting intense pressure on that country’s healthcare system. At the same time, the virus landed a devastating blow to the Chinese economy, sharply reducing China’s exports to the rest of the world.

It’s no secret that Chinese pharmaceutical factories turn out some of the active ingredients for popular prescription medications sold in the United States and elsewhere around the world. Among these medications are some of the PDE5-inhibiting drugs prescribed to treat erectile dysfunction.

A Turnaround in China?

Recent news reports out of China indicate that Beijing’s draconian measures to halt the spread of the coronavirus are beginning to have a positive effect. However, it would be foolhardy to suggest that China is now free of the effects of COVID-19 and can get back to business as usual.

A couple of days with no new infection reports is heartening news, of course, but so little is known about this coronavirus that it’s not safe to say whether this good news will last. Or after a period of dormancy, could the virus attack again with renewed vigor?

Implication of Uncertainties

These uncertainties cast doubt over the reliability of the pharmaceutical ingredient supply chain out of China. And it also puts into question the Chinese demand for finished prescription drugs produced outside China. After all, China is one of America’s leading export markets. In 2018, U.S. exports to China totaled $120.3 billion.

While not yet hard hit by COVID-19, India is also the source of some of the active ingredients used in popular prescription drugs, especially generics, including ED medications. India, in turn, is heavily reliant on some raw materials it imports from China. While reported infections from India are low thus far, that may be more a reflection of inadequate testing than a true picture of the virus’s real impact in that country.

Generics Might Be Hit Hardest

In its mid-February assessment of COVID-19’s impact on the prescription drug supply chain, Moody’s Investor Service said the greatest threat was probably a shortage of active ingredients for generic drugmakers. This would certainly lead to increased prices for all prescription drugs affected, including ED medications.

If the latest Chinese reports of a sharp drop in the rate of new infections hold up, then there is some hope that its pharmaceutical manufacturers can return to normal capacity without any serious supply chain disruptions.

In light of the uncertainty about the impact of COVID-19 on the supply of active ingredients for certain ED drugs, price hikes for those drugs most affected are likely.

A Good Time to Stock Up

That would make this an ideal time to stock up on the ED drugs of your choice. If the convenience and privacy of ordering those drugs online appeals to you, check out all the services available from, a longtime medical facilitator.

Prices at eDrugstore include not just the drugs you’re ordering but a number of time- and money-saving services as well. Shipping and handling are free, sparing you the hassle of trips to and from your local pharmacy.

If you don’t yet have a prescription, take advantage of eDrugstore’s free online consultation service. This service sets up an online telemedicine visit with a physician licensed to practice in your state. If the doctor determines that you’re an appropriate candidate for the drug, a prescription will be authorized.

That prescription is then routed by eDrugstore to a licensed U.S. pharmacy, which will fill the prescription and ship it off to the destination of your choice. To learn more about all these services, visit eDrugstore’s Erectile Dysfunction page.

Don Amerman has spent more than three decades in the business of writing and editing. During the last 15 years, his focus has been on freelance writing. For almost all of his writing, He has done all of his own research, both online and off, including telephone and face-to-face interviews where possible. Don Amerman on Google+